Quantcast
Last updated on April 16, 2014 at 11:25 EDT

Latest Fingolimod Stories

2010-01-06 07:30:00

CAMBRIDGE, Mass., Jan. 6 /PRNewswire/ -- Sermo (http://www.sermo.com), the world's largest online physician's community, today announced a new Sermo Event(TM) Report assessing physician perception of FDA's "refuse to file" (RTF) letter on EMD Serono's Cladribine tablets and its potential impact, if any, on Novartis' oral MS agent in development; Fingolimod. Cladribine is expected to be one of the first oral agents to be approved for the treatment of relapsing and remitting multiple...

2009-09-09 07:00:00

WALTHAM, Mass., Sept. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to its infrequent dosing and positive efficacy, nearly 90 percent of surveyed neurologists indicate they will prescribe Merck Serono/EMD Serono's oral cladribine for the treatment of multiple sclerosis. The new Physician & Payer Forum report entitled Multiple Sclerosis: How Will Clinician Attitudes and...

2008-09-02 12:00:34

Research and Markets (http://www.researchandmarkets.com/research/f0d42d/cns_drug_discoveri) has announced the addition of the "CNS Drug Discoveries: Multiple Sclerosis Chapter" report to their offering. This chapter of CNS Drug Discoveries focuses on the multiple sclerosis market. With the launch of up to 12 new disease-modifying agents, three vaccines and one novel drug designed to treat the symptoms of multiple sclerosis (MS) and improve quality of life, the MS market is in an...